A Phase I Study of MK0752, a Notch Inhibitor, in Patients With Metastatic or Locally Advanced Breast Cancer and Other Solid Tumors.

Trial Profile

A Phase I Study of MK0752, a Notch Inhibitor, in Patients With Metastatic or Locally Advanced Breast Cancer and Other Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Apr 2014

At a glance

  • Drugs MK 0752 (Primary)
  • Indications Advanced breast cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 24 Apr 2012 Actual patient number (103) added as reported by ClinicalTrials.gov.
    • 07 Sep 2011 Actual end date (August 2011) added as reported by ClinicalTrials.gov.
    • 07 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top